GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veritas In Silico Inc (TSE:130A) » Definitions » Other Current Receivables

Veritas In Silico (TSE:130A) Other Current Receivables : 円0.0 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Veritas In Silico Other Current Receivables?

Veritas In Silico's Other Current Receivables for the quarter that ended in Jun. 2024 was 円0.0 Mil.


Veritas In Silico Other Current Receivables Historical Data

The historical data trend for Veritas In Silico's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veritas In Silico Other Current Receivables Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23
Other Current Receivables
- - -

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24
Other Current Receivables Get a 7-Day Free Trial - - - - -

Veritas In Silico Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Veritas In Silico Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Veritas In Silico's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Veritas In Silico Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.

Veritas In Silico Headlines

No Headlines